Kemp Dolliver
Stock Analyst at Brookline Capital
(0.46)
# 4,212
Out of 5,118 analysts
17
Total ratings
30.77%
Success rate
-17.83%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals | Upgrades: Buy | $17 | $8.19 | +107.57% | 3 | Dec 18, 2025 | |
| RNTX Rein Therapeutics | Downgrades: Hold | n/a | $1.14 | - | 1 | Aug 19, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $18 | $5.37 | +235.20% | 1 | Jul 21, 2025 | |
| LSTA Lisata Therapeutics | Maintains: Buy | $20 → $32 | $1.95 | +1,541.03% | 1 | Jul 15, 2025 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $1.85 | +94.59% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.00 | +1,700.00% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $1.98 | +1,485.86% | 1 | Jan 25, 2024 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $67.34 | +48.50% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $1.48 | +3,751.35% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $4.38 | +470.78% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.82 | +289.00% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.62 | +1,183.08% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.65 | +770.44% | 1 | Feb 2, 2022 |
Verrica Pharmaceuticals
Dec 18, 2025
Upgrades: Buy
Price Target: $17
Current: $8.19
Upside: +107.57%
Rein Therapeutics
Aug 19, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.14
Upside: -
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $5.37
Upside: +235.20%
Lisata Therapeutics
Jul 15, 2025
Maintains: Buy
Price Target: $20 → $32
Current: $1.95
Upside: +1,541.03%
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $1.85
Upside: +94.59%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.00
Upside: +1,700.00%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $1.98
Upside: +1,485.86%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $67.34
Upside: +48.50%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $1.48
Upside: +3,751.35%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $4.38
Upside: +470.78%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $4.82
Upside: +289.00%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.62
Upside: +1,183.08%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.65
Upside: +770.44%